Shockwave Medical down as brokerage raises concern over long-term growth

Shockwave Medical

08/11/2022 18:49

** Shockwave Medical Inc's shares  SWAV.O  fall 7.5% to
$256.6 
    ** Brokerage Oppenheimer doubts any new clinical trials
financed by the medical device maker will be rigorous in nature 
    ** "Lack of reorder metrics on (earnings) call raises
question," said Oppenheimer analyst Suraj Kalia
    ** SWAV raised 2022 sales guidance to the range of $483
mln-$488 mln from $465 mln-$ 475 mln, missing our estimates of
$494 mln to $476 mln - Oppenheimer
    ** Including session losses, stock up ~45% YTD
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))